^
Association details:
| Biomarker: | PD-L1 overexpression + BRAF V600E |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Mekinist (trametinib) (MEK inhibitor) + Tafinlar (dabrafenib) (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation
Published date:
08/08/2022
Excerpt:
...the patient was diagnosed with an AJCC 8th stage IIIA (cT1cN2M0) primary left lung adenocarcinoma harboring BRAF V600E and PD-L1 TPS 90%+ after a complete initial evaluation….Postoperative adjuvant treatment with dabrafenib and trametinib was prescribed 1 month after surgery....During the disease course, he only experienced aforementioned pyrexia, which lasted 10 days and resolved with use of antibiotics and the temporary interruption of bi-targeted therapy. No other toxic side effects were observed. The patient currently remains in good condition and complete remission at 3 months after surgery. The case presented here supports the use of neoadjuvant treatment with BRAF inhibitors in local advanced non-small lung cancer with BRAF V600E mutation.
DOI:
https://doi.org/10.3389/fonc.2022.961539
